Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.59 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.58 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.56 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.56 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.56 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.56 |
| ▸ | CYP2J2 | P51589 | 13/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265221 | 0.99 | CYP2J2 (0.78) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL6826935 | 0.91 | LMNA (0.71) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL2456116 | 0.91 | CYP2J2 (0.73) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL2994361 | 0.91 | CYP2J2 (0.66) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL2235075 | 0.91 | CYP2J2 (0.74) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| Hydrochloric Acid SCHEMBL3681404 | 0.90 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL48803 | 0.90 | CYP2J2 (0.75) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL14622763 | 0.90 | CYP2J2 (0.67) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL1395734 | 0.89 | CYP2J2 (0.84) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 | |
| SCHEMBL18765452 | 0.88 | CYP2J2 (0.82) | CYP2J2CYP3A4CYP2C9CYP2B6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261209-A1 | Novel crystalline forms of 4-[4-[4- hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenene acetic acid and its hydrochloride | Dr. Reddy's Laboratories Ltd. (IN) | 2010-12-15 | — | — | EP | disclosed |
| US-20100174085-A1 | CRYSTALLINE POLYMORPHIC FORMS OF FEXOFENADINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-07-08 | — | — | US | disclosed |
| US-7700779-B2 | Crystalline forms of fexofenadine and its hydrochloride | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-04-20 | — | — | US | disclosed |
| US-6903232-B2 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-α, α-dimethylphenylacetic acid | AUROBINDO PHARMA LTD. (IN) | 2005-06-07 | — | — | US | disclosed |
| US-20040077683-A1 | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-04-22 | — | — | US | disclosed |
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | AUROBINDO PHARMA LIMITED (IN) | 2004-04-22 | — | — | US | disclosed |
| EP-1399422-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINYL] -1-HYDROXYBUTYL] -A,A-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | Dr. Reddy's Laboratories Ltd. (IN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002102777-A2 | NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | CMA1, HRH1, HRH2 | HRH1 2/4885DRD3 1280/4885DRD2 865/4885 |
| US-20100174085-A1 | CRYSTALLINE POLYMORPHIC FORMS OF FEXOFENADINE | CYP4F3, CYP4F2, UBE2V1 | HRH1 24/4885DRD3 2157/4885DRD2 1644/4885 |
| US-20040077683-A1 | Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1- piperidinyl]-1-hydroxybutyl]-$g(a)-dimethylbenzene acetic acid and its hydrochloride | HRH2, CYP4B1, CYP1B1 | HRH1 6/4885DRD3 2024/4885DRD2 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.